The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IACH Focus on Leukemia 2020 | Highlights in leukemia research: MRD as a prognostic factor
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the importance of measurable residual disease (MRD). In recent years, MRD has been used as a prognostic factor in acute lymphoblastic leukemia (ALL). However, in acute myeloid leukemia (AML), MRD negativity is harder to achieve. There have been other signs of progress in chronic leukemias, such as the use of ibrutinib and venetoclax. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
